Antidepressant Shines in Phase 2 Trial, but FDA Voices Concerns Antidepressant Shines in Phase 2 Trial, but FDA Voices Concerns

Although an antidepressant combining dextromethorphan and bupropion delayed time to depression relapse in a phase 2 trial, its upcoming FDA action date may be in jeopardy.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Psychiatry News Source Type: news